'For jet lag and insomnia': Psilocybin to be prescribed, melatonin to be sold over-the-counter
Psilocybin will still be an "unapproved medicine" but will be able to be granted under the authority of one specific highly experienced psychiatrist.
Melatonin is a natural hormone that helps induce sleep, and is used to treat insomnia and jet lag, but has been classified as a prescription-only medicine in New Zealand.
It will be available in pharmacies as pills up to 5mg in packs with up to 10 days' supply, or pills up to 3mg. "Modified release doses" - pills, capsules, gels and medical devices which allow the drug to be administered over a specific period - could also be available with dosages of up to 2mg.
No specific date has been set for when the changes will take effect.
Associate Health Minister David Seymour announced the decisions on Wednesday afternoon, noting they were made by MedSafe rather than politicians.
"Certainly I've discussed with some of them ... some of them were very enthusiastic about the melatonin but ultimately they respect that it's a technical decision for MedSafe."
He said melatonin would become available once manufacturers began to export it to New Zealand.
"You'll be able to go to any pharmacy and buy melatonin for jet lag and insomnia just as soon as it's available over the counter in New Zealand. Part of the purpose of my announcement today is to call on the melatonin manufacturers of the world to apply to bring their products into our country," Seymour said.
"When we did this with pseudoephedrine, it was a matter of months before products were on the shelves and I hope we can beat that record.
"Kiwis shouldn't be left counting sheep or desperate for options when other countries are already using these medicines. The government is committed to putting patients first ... this is a commonsense decision that will make melatonin more accessible in New Zealand than in many other countries."
The change for psilocybin was a huge win for people with depression who had tried everything else, Seymour said.
"If a doctor believes psilocybin can help, they should have the tools to try. The psychiatrist involved has previously prescribed psilocybin in clinical trials and will operate under strict reporting and record-keeping requirements."
He said it would initially only be available from one specific psychiatrist, but he hoped more would apply.
"Psilocybin is a medicine that can treat untreatable depression. It was first researched in the 1950s and '60s and more recently there's been extensive research and approvals by the FDA in the United States to be able to use these types of medicines.
"Fair to say it's been driven by people in the profession - there's a lot of people very passionate about this because untreatable depression's an awful thing and there are clinicians who say there's stuff happening in the rest of the world and we need to be part of it."
He had never taken either of them, nor pseudoephedrine.
"No. No I have not inhaled melatonin but maybe I will. I've had some recent issues with jet lag of my own so hopefully in the future I'll be able to," Seymour said.
"I used to go mushroom hunting with my dad as a very small kid, but I don't think we found any."
The melatonin changes were confirmed in regulations gazetted by Medsafe group manager Chris James.
The psilocybin changes were not yet gazetted, but it will mark the first time psilocybin will be legally available in New Zealand outside of clinical trials.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Techday NZ
an hour ago
- Techday NZ
DeepHealth gains FDA approval for remote scanning in ultrasound
DeepHealth has received FDA 510(k) clearance for its TechLive remote scanning solution, enabling centralised operations and supervision for MR, CT, PET/CT and, for the first time, Ultrasound procedures. Addressing staffing challenges The company's announcement comes as radiology workloads continue to rise, with the number of qualified technologists failing to keep pace. This disparity has contributed to staffing gaps and periods of MRI room closures, limiting access to complex scans and procedures for patients. DeepHealth aims to address these issues by equipping technologists with the ability to operate scanning equipment for multiple locations remotely. This model enables improved operational efficiency and extends the scope of experienced staff to more cases across different centres. Results from pilot study During a pilot deployment at 64 RadNet sites in the New York area, DeepHealth's TechLive solution contributed to a 42 percent decrease in MRI room closure hours during the second quarter of 2025, compared with the same period in 2024. According to DeepHealth, this resulted in more timely scans for patients and improved access to complex procedures. The company has also reported that, through remote expert involvement, TechLive contributed to an increase in the number of complex imaging procedures performed at these locations. The TechLive system currently connects over 300 RadNet MR, CT, PET/CT, and Ultrasound systems. By implementing real-time remote expertise, experienced senior sonographers and physicians can now guide on-site technologists through complex ultrasound cases - a modality noted for its reliance on operator skill and immediate decision-making. Company perspectives "TechLive represents a paradigm shift in how we approach imaging operations. By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. Operational impact TechLive has been introduced to streamline imaging operations, with specific attention to enhancing operational efficiency, extending operating hours for centres, and improving access to more complex diagnostic and therapeutic procedures. The solution's extension to Ultrasound marks the first industry application of remote scanning and supervision for this modality. By matching expert staff to complex cases in real time, DeepHealth seeks to increase patient throughput and maintain quality standards, while also helping care providers manage ongoing labour shortages and wage pressures in health services. Sector implications The increasing adoption of remote scanning solutions comes as healthcare providers face higher demand for complex imaging and persistent difficulty in recruiting qualified technologists. As radiology services evolve, solutions like TechLive are being considered as part of long-term strategies to maintain patient access and support a sustainable operational model. Follow us on: Share on:
RNZ News
19 hours ago
- RNZ News
Advertising unapproved medicines not legal, despite government claim
In a statement, Minister for Regulation David Seymour said the restriction on advertising new medicines at medical conferences "is being removed". Photo: RNZ / Mark Papalii Despite a government announcement suggesting it has lifted the ban on advertising unapproved medicines, it remains a criminal offence, warn legal experts. In a joint media release with Health Minister Simeon Brown, Minister for Regulation David Seymour welcomed "confirmation" of two major medical conferences in New Zealand next year, following the rule change to allow advertising of unapproved medicines at trade shows. The Ministry for Regulation had found the "overly cautious approach" was out of step with other recognised jurisdictions, and the government "acted fast to fix it", Seymour said. However, leading intellectual property lawyer Paul Johns - head of litigation for Pearce IP - cautioned the law had not yet changed. "If I were the organiser of these conferences and had seen those media releases, I would be making sure that my sponsors were aware that in fact the law has not changed and any medicines they want to advertise ought to be approved, because the consequences are criminal - there are fines and even imprisonment. "I don't think you would get that far, but they're there." Parliament was currently considering some amendments to the Medicines Act (to enable faster approval of drugs and widen powers for nurse prescribers) but there was nothing to do with advertising, he said. "It's still possible that the government could submit an amendment paper and put this advertising thing in there as well, but they haven't. So they appear to have a policy but they've done nothing about it in terms of legislation." The "great irony" was that under the Therapeutic Products Act - which was repealed by the current administration - the government could have simply introduced new regulations allowing such advertising, Johns noted. "But now they need to amend the Medicines Act." Others have pointed out that medical conferences were planned years in advance, so the new policy could not have been the deciding factor for next year's bookings. In a written response to RNZ's questions, Minister Seymour said the restriction on advertising new medicines at medical conferences "is being removed". "Ending New Zealand's prohibition on advertising medicines at medical conferences and trade shows has sent a message that New Zealand is open for business. That's exactly what medical conference organisers needed to hear, with two already confirmed for 2026." Medicines New Zealand chief executive Dr Graeme Jarvis said New Zealand had been missing out on conferences worth up to $90 million a year because it was impossible to run trade shows alongside them. "So you're actually losing out on not only the income you would get from running the conference and trade show here, but also the tourism spend as well." Clinicians had also been missing out. "Doctors here aren't getting exposed to all of the latest and greatest in terms of conferences, scientific exchange, the information and updates on all sorts of things." However, Auckland University associate professor of psychological medicine David Menkes said it was "misleading" to suggest doctors did not already have access to the latest information about new treatments. "But usually that information comes not from a company rep, it will come from an expert who's presenting as a colleague, rather than as an exhibitor or a sponsor of a conference." The academic psychiatrist said doctors liked to "believe they can't be swayed by corporate largesse" - but studies showed they were not immune. "That's why academic journals require peer review and disclosure of interests." Menkes is a long-time critic of New Zealand's permissive marketing regime : it is the only OECD country - apart from the United States - to allow direct-to-consumer advertising of medicines. Further loosening of the rules could compound the risk of over-prescribing, he said. "You don't want to be held up by red tape and bureaucracy, right? But you also want to have checks and balances in place. "I'm afraid this new policy doesn't have adequate checks and balances against overt promotional behaviour by vested interests." Seymour's office was unable to say when the government was planning to turn the policy into something Parliament could consider.
RNZ News
2 days ago
- RNZ News
Two-month-old Bellamere Arwyn Duncan's death 'must be a turning point', says pharmacist
Bellamere Duncan died at Starship Hospital on 19 July. Photo: Supplied The death of a two-month-old baby who died after being given medication that was more than 13 times the prescribed dose is a "symptom of a much deeper, systemic issue," a member of the national executive of the Pharmaceutical Society says. RNZ earlier revealed Bellamere Arwyn Duncan died at Starship Hospital on 19 July. A Manawatū pharmacy dispensed an adult dosage of phosphate to the two-month-old's parents. A provisional post mortem report said she died from phosphate toxicity. The revelations have prompted the Ministry of Health and Health New Zealand to "urgently" undertake a joint review into the incident with MedSafe visiting the pharmacy to ensure it was safe to continue operating. The Pharmacy Council, which is also investigating, said it was "clear that an awful error has occurred". On Friday, the owner of the pharmacy emailed Bellamere's parents and told them an intern pharmacist misread the prescribed dosage of medication. Afterwards, a trainee technician, who was handling a phosphate product for the first time, did not notice the dosage error. Then a registered pharmacist who carried out the final check did not pick up that the prescription was for an infant and that it was new medication. The intern pharmacist has since been suspended, and the registered pharmacist has resigned. Do you know more? Email Lanny Wong a pharmacist, director of Mangawhai Pharmacy and a member of the national executive of the Pharmaceutical Society, told RNZ on Tuesday Bellamere's death was "not simply a one-off mistake". "It's a symptom of a much deeper, systemic issue. The current model prioritises volume over value, this incentivises speed at the expense of safety. "For years, community pharmacies have grappled with operating under this fundamentally flawed funding system, marked by chronic underinvestment and relentless workload pressures. Skilled staff are increasingly difficult to retain, and experienced pharmacists are burning out or leaving the profession altogether. The very people relied upon to be the final checkpoint before a medicine reaches a patient are now overstretched, under-resourced, and unsupported." CAPTION: Bellamere Duncan's parents were given an adult dosage of phosphate by the pharmacy. Photo: Supplied Wong said in healthcare there were multiple layers of safeguards that were meant to save an error from happening. "But when there are gaps in every layer, caused by workload pressures, fatigue, underinvestment or broken systems and those gaps align, the error breaks through." Pharmacists were being asked to interpret complex prescriptions, perform clinical calculations, and provide personalised counselling, often while working under intense pressure and tight deadlines, she said. "In Bellamere's case, it appears the pharmacist had to calculate a specialised paediatric dose and explain a precise paediatric-dosing schedule to the whānau. This is work that requires expertise, care, and time, and yet the pharmacy was reimbursed less than the cost of a cup of coffee. That's not just unsustainable. It's unsafe." She said Bellamere's death "must be a turning point". "It's not just about fixing one pharmacy or one process, it's about fixing the system around pharmacy. "That means investing in safety, funding time to think, check and counsel, and designing a workforce strategy that ensures every community has access to skilled, supported pharmacists." [h ]The medication error In their email to Bellamere's parents the owner of the Manawatū Pharmacy included a summary of what happened. The owner said the pharmacy's standard dispensing process involved intern pharmacists entering each prescription into the dispensary computer. The pharmacy used a dispensing system called Toniq. A technician would then use the information in Toniq and the prescription to identify the medication and put the correct amounts in containers. The labels were then printed out and placed in a basket with the original prescription and the medication. A registered pharmacist would then check the prescription, the labels and the medication itself before it was given to the patient. The owner said the pharmacy received the prescription by email on 1 July from Palmerston North Hospital. The prescription was entered into Toniq by an intern pharmacist. "This person unfortunately misread the prescribed dosage and entered the prescription dose as '1 tablet twice daily' rather than '1.2 mmol twice daily'," the owner said. The Toniq system then generated an original label for the prescription. "This includes a warning label with the patient's age, if they are under 18 years old, and if the patient has not been prescribed the medication before. "The second warning prompts the checking pharmacist to counsel (speak with) the patient or their caregiver about how to take the medication." The product was supplied in tubes of 20 tablets. The trainee technician printed out three further labels. They were to be placed on the three tubes that were being dispensed. "This was the trainee technician's first time handling a phosphate product. She was also unfamiliar with the mmol dosage. She did not notice the dosage error as a result. She put the original prescription, labels and the medication in a basket on the dispensing bench for the registered pharmacist to check. "Unfortunately, the original label and the warning label was not kept with other items." The registered pharmacist who carried out the final check did not pick up that the medication was for an infant, the owner said. "In addition, it was not identified that this was a new medication. The fact that the warning label was not retained contributed to this error." The owner said the intern pharmacist had been suspended by the Pharmacy Council. The registered pharmacist had taken leave and then resigned. "This person does not intend to return to work in the immediate future," the owner said. The pharmacy was "urgently re-evaluating our dispensing and checking protocols and reinforcing safety checks at every stage". "We are actively recruiting additional staff to help manage our workloads. In addition, we are engaging an independent pharmacist from outside the Manawatū region to conduct a full review of our dispensing procedures and provide further guidance on system improvements." The owner said the pharmacy was "fully co-operating" with investigations being carried out by MedSafe, the Pharmacy Council and the police on behalf of the coroner. The owner signed off the email with "heartfelt apologies and regret". Bellamere's parents Tempest Puklowski and Tristan Duncan said after reading the email they did not blame the intern pharmacist for what happened. "My first initial reaction after reading it was I felt really bad for the intern," Puklowski said. "I don't blame him for the mistakes. I blame whoever was meant to be looking over his shoulder, whoever put him in that responsibility and just left him to it." Puklowski said it should have been picked up that the medication was for a baby. "It just seems like there's something lacking there that could have avoided it being missed or messed up," she said. Duncan said the system "needs to be better". Tempest said she remained "frustrated and angry" about her daughter's death. "It's just an endless sort of questioning of how and where it went wrong, to the point of, yeah, how could it have been avoided? "Obviously, those questions don't do much now, which then brings on the sadness of just knowing that she could still be here if these things were pulled up on initially, if maybe the intern wasn't left just to do the job by themselves. Or if you know something else is put in place, we would've never even gotten it and then we wouldn't be beating ourselves up for giving it to her." Duncan said the past two weeks since Bellamere's death had been "really hard". "Just empty is the only word that really comes to mind," he said. "It's unfair. Just stolen away by a singular document. That's what it comes down to." Puklowski said the couple "don't really know what to do with ourselves really". They were now waiting to see what happened with the multiple investigations that are under way. "I want things to change," Duncan said.
